Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Prothena Corp (NQ: PRTA )

16.92 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 15, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 16.92
Bid (Size) 16.50 (2)
Ask (Size) 18.10 (18)
Prev. Close 16.92
Today's Range 16.92 - 16.92
52wk Range 15.52 - 55.89
Shares Outstanding 45,047,449
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Breaking Down Prothena Corp: 4 Analysts Share Their Views
Via Benzinga
Dow Dips 300 Points; Emcore Shares Spike Higher
Via Benzinga
Topics Stocks
Exposures US Equities

Performance

YTD
-56.10%
-56.10%
1 Month
-22.70%
-22.70%
3 Month
-29.88%
-29.88%
6 Month
-20.71%
-20.71%
1 Year
-67.66%
-67.66%

More News

Read More
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
Crude Oil Moves Higher; Prime Medicine Shares Spike Higher
Via Benzinga
Exposures Fossil Fuels
Prothena Announces Leadership Team Updates
From Prothena Corporation plc
Via Business Wire
Demystifying Prothena Corp: Insights From 8 Analyst Reviews
Via Benzinga
Decoding 6 Analyst Evaluations For Prothena Corp
Via Benzinga
Prothena to Participate in Upcoming Healthcare Conferences
From Prothena Corporation plc
Via Business Wire
PRTA Stock Earnings: Prothena Corp Beats EPS, Beats Revenue for Q2 2024
Via InvestorPlace
Prothena Reports Second Quarter 2024 Financial Results and Business Highlights
From Prothena Corporation plc
Via Business Wire
Prothena to Report Second Quarter 2024 Financial Results on August 8
From Prothena Corporation plc
Via Business Wire
Prothena Corp: Q4 Earnings Insights
Via Benzinga
Earnings Scheduled For February 15, 2024
Via Benzinga
Eli Lilly Drags Alzheimer's Stocks Prothena, Eisai Lower Despite FDA Win
Via Investor's Business Daily
Exposures Product Safety
Prothena Announces Bristol Myers Squibb Opt-in for Exclusive Global License for PRX019, the Second Program from Global Neuroscience Research and Development Collaboration
From Prothena Corporation plc
Via Business Wire
PRTA Stock Earnings: Prothena Corp Misses EPS, Misses Revenue for Q1 2024
Via InvestorPlace
Prothena Reports First Quarter 2024 Financial Results and Business Highlights
From Prothena Corporation plc
Via Business Wire
Prothena to Report First Quarter 2024 Financial Results on May 8
From Prothena Corporation plc
Via Business Wire
Prothena Announces Review on Birtamimab Mechanism of Action and Pharmacological Characteristics Published in Leukemia & Lymphoma
From Prothena Corporation plc
Via Business Wire
Race To Treat Alzheimer's Disease Is Heating Up Despite Eli Lilly's Setback
Via Investor's Business Daily
Exposures Product Safety
Prothena to Participate in Upcoming Healthcare Conferences
From Prothena Corporation plc
Via Business Wire
Prothena Appoints David Ford to Newly Created Chief People Officer Position
From Prothena Corporation plc
Via Business Wire
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Prothena Announces Appointment of Daniel G. Welch as Director and Chair Designate
From Prothena Corporation plc
Via Business Wire
Prothena Reports Fourth Quarter and Full Year 2023 Financial Results, and Provides Financial Guidance and Business Highlights
From Prothena Corporation plc
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.